长链非编码RNA IGF2BP2-AS1通过调控miR-375表达对喉癌细胞迁移及增殖的影响

doi:10.3760/cma.j.issn.1007-1245.2024.06.018

摘要/Abstract

摘要：

目的　探讨长链非编码RNA（lncRNA）胰岛素样生长因子2 mRNA结合蛋白2（IGF2BP2）-AS1通过调控微RNA-375（miR-375）表达对喉癌细胞迁移和增殖的影响。方法　研究时间为2022年1月至2023年11月，研究地点为郑州大学附属洛阳中心医院中心实验室，研究类型为基础研究。实时荧光定量PCR（qPCR）检测喉癌细胞系AMC-NH-8、TU159、TU138、TU686和支气管上皮细胞系16HBE中IGF2BP2-AS1的表达。以TU686细胞为研究对象，将TU686细胞分为si-NC组和si-IGF2BP2-AS1组，采用IGF2BP2-AS1小干扰RNA下调IGF2BP2-AS1表达水平。划痕愈合实验和CCK-8法分析敲降IGF2BP2-AS1对TU686细胞迁移及增殖的影响。双荧光素酶报告基因实验验证IGF2BP2-AS1与miR-375的靶向关系。qPCR检测敲降IGF2BP2-AS1对miR-375表达的影响。Western blotting检测细胞中迁移蛋白N-钙黏着蛋白（N-Cadherin）、叉头框蛋白C2（FOXC2）和增殖蛋白CDK2、细胞周期蛋白A（Cyclin A）的表达。统计学方法采用单因素方差分析、t检验。结果　与16HBE细胞相比，IGF2BP2-AS1在喉癌细胞系中均高表达（F=37.42，P<0.01）。si-IGF2BP2-AS1组TU686细胞划痕愈合率低于si-NC组［（28.166.13）%比（65.083.82）%］，差异有统计学意义（t=5.11，P<0.01）。在铺板后第2、3、4、5天，si-IGF2BP2-AS1组TU686细胞增殖能力均低于si-NC组（t=3.83、3.17、3.02、6.31，均P<0.01）。IGF2BP2-AS1-Wt中，miR-375组相对荧光素酶活性低于miR-NC组（t=8.95，P<0.01）。si-IGF2BP2-AS1组TU686细胞中miR-375表达高于si-NC组［（4.950.49）比（1.020.40）］，差异有统计学意义（t=6.23，P<0.01）。敲降IGF2BP2-AS1后TU686细胞中迁移蛋白N-Cadherin、FOXC2表达与增殖蛋白CDK2、Cyclin A表达均低于si-NC组。结论　IGF2BP2-AS1在喉癌细胞系中呈高表达，敲降IGF2BP2-AS1通过调控miR-375表达抑制喉癌TU686细胞的迁移及增殖能力。

关键词:

喉癌, 长链非编码RNA, IGF2BP2-AS1, miR-375, 迁移, 增殖

Abstract:

Objective　To investigate the effect of long non-coding RNA (lncRNA) insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) -AS1 on the migration and proliferation of laryngeal cancer cells by regulating the expression of microRNA-375 (miR-375). Methods　The research period was from January 2022 to November 2023, the research place was the central laboratory of Luoyang Central Hospital Affiliated to Zhengzhou University, and the research type was basic research. qPCR was used to detect the expression of IGF2BP2-AS1 in laryngeal cancer cell lines AMC-NH-8, TU159, TU138, and TU686 and bronchial epithelial cell line 16HBE. Taking TU686 cells as the research object, the TU686 cells were divided into a si-NC group and a si-IGF2BP2-AS1 group, and IGF2BP2-AS1 small interfering RNA was used to down-regulate the expression level of IGF2BP2-AS1. The scratch healing assay and CCK-8 method were used to analyze the effects of knocking down IGF2BP2-AS1 on the migration and proliferation of TU686 cells. Dual luciferase reporter gene experiment verified the targeting relationship between IGF2BP2-AS1 and miR-375. qPCR was used to detect the effect of knocking down IGF2BP2-AS1 on the expression of miR-375. Western blotting was used to detect the expressions of migration proteins (N-Cadherin and FOXC2) and proliferation proteins (CDK2 and Cyclin A) in cells. One-way ANOVA and t test were used. Results　Compared with 16HBE cells, IGF2BP2-AS1 was highly expressed in laryngeal cancer cell lines (F=37.42, P<0.01). The scratch healing rate of TU686 cells in the si-IGF2BP2-AS1 group was lower than that in the si-NC group [(28.16±6.13)% vs. (65.08±3.82)%], with a statistically significant difference (t=5.11, P<0.01). The proliferation capacity of TU686 cells in the si-IGF2BP2-AS1 group was lower than that in the si-NC group 2, 3, 4, and 5 days after planking (t=3.83, 3.17, 3.02, and 6.31, all P<0.01). In IGF2BP2-AS1-Wt, the relative luciferase activity of the miR-375 group was lower than that of the miR-NC group (t=8.95, P<0.01). The expression of miR-375 in TU686 cells in the si-IGF2BP2-AS1 group was higher than that in the si-NC group [(4.95±0.49) vs. (1.02±0.40)], with a statistically significant difference (t=6.23, P<0.01). Compared with the si-NC group, the expression levels of migration proteins (N-Cadherin and FOXC2) and proliferation proteins (CDK2 and Cyclin A) were reduced in TU686 cells after knocking down IGF2BP2-AS1. Conclusion　IGF2BP2-AS1 is highly expressed in laryngeal cancer cell lines, and knocking down IGF2BP2-AS1 inhibits the migration and proliferation of laryngeal cancer TU686 cells by regulating the expression of miR-375.

Key words:

Laryngeal cancer, Long-chain non-coding RNA, IGF2BP2-AS1, miR-375, Migration, Proliferation

王挺张杨郭洁范崇盛刘亚芳.

长链非编码RNA IGF2BP2-AS1通过调控miR-375表达对喉癌细胞迁移及增殖的影响 [J]. 国际医药卫生导报, 2024, 30(6): 968-973.

Wang Ting, Zhang Yang, Guo Jie, Fan Chongsheng, Liu Yafang.

Long non-coding RNA IGF2BP2-AS1 regulates the migration and proliferation of laryngeal cancer cells through miR-375 [J]. International Medicine and Health Guidance News, 2024, 30(6): 968-973.

参考文献

[1] Zhao L, Zheng Y, Zhang L,et al. E2F1-induced FTH1P3 promoted cell viability and glycolysis through miR-377-3p/LDHA axis in laryngeal squamous cell carcinoma[J]. Cancer Biother Radiopharm, 2022 ,37(4):276-286. DOI: 10.1089/cbr.2020.4266.
[2] Ren P, Niu X, Zhao R,et al. Long non-coding RNA AGAP2-AS1 promotes cell proliferation and invasion through regulating miR-193a-3p/LOXL4 axis in laryngeal squamous cell carcinoma[J]. Cell Cycle, 2022 ,21(7):697-707. DOI: 10.1080/15384101.2021.2016197.
[3] Liu Y, Zhao F, Tan F,et al. HNF1A-AS1: a tumor-associated long non-coding RNA[J]. Curr Pharm Des, 2022,28(21):1720-1729. DOI: 10.2174/1381612828666220520113846.
[4] Dong Z, Yang L, Lu J,et al. Downregulation of LINC00886 facilitates epithelial-mesenchymal transition through SIRT7/ELF3/miR-144 pathway in esophageal squamous cell carcinoma[J]. Clin Exp Metastasis, 2022 ,39(4):661-677.DOI: 10.1007/s10585-022-10171-w.
[5] Abdi E, Latifi-Navid S. LncRNA polymorphisms and urologic cancer risk[J]. Environ Mol Mutagen, 2022 ,63(4):190-203. DOI: 10.1002/em.22472.
[6] Azizidoost S, Ghaedrahmati F, Sheykhi-Sabzehpoush M, et al. The role of LncRNA MCM3AP-AS1 in human cancer[J]. Clin Transl Oncol, 2023 ,25(1):33-47. DOI: 10.1007/s12094-022-02904-w.
[7] Li L, Han J, Zhang S,et al. KIF26B-AS1 regulates TLR4 and activates the TLR4 signaling pathway to promote malignant progression of laryngeal cancer[J]. J Microbiol Biotechnol, 2022 ,32(10):1344-1354. DOI: 10.4014/jmb.2203.03037.
[8] Ma X, Ren H, Zhang Y,et al. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway[J]. Environ Toxicol, 2022 ,37(12):3013-3027. DOI: 10.1002/tox.23656.
[9] Zhao F, Liu Y, Tan F,et al. MIR4435-2HG: a tumor-associated long non-coding RNA[J]. Curr Pharm Des, 2022,28(25):2043-2051. DOI: 10.2174/1381612828666220607100228.
[10] Ye C, Chen YG, Qin SF,et al. Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer[J]. Transl Androl Urol, 2022 ,11(5):643-658. DOI: 10.21037/tau-22-99.
[11] Ding K, Zheng Z, Han Y,et al. Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer[J]. Cell Cycle, 2022 ,21(23):2533-2549. DOI: 10.1080/15384101.2022. 2103898.
[12] Tong S, Wang X, Guo X,et al. Knockdown of lncRNA IGF2BP2-AS1 inhibits proliferation and migration of oral squamous cell carcinoma cells via the Wnt/β-catenin pathway[J]. J Oral Pathol Med, 2022,51(3):272-280.DOI: 10.1111/jop.13248.
[13] Li Y, Tang B, Lyu K,et al. Low expression of lncRNA SBF2-AS1 regulates the miR-302b-3p/TGFBR2 axis, promoting metastasis in laryngeal cancer[J]. Mol Carcinog, 2022 ,61(1):45-58. DOI: 10.1002/mc.23358.
[14] Li Y, Pan B, Guo X,et al. Prognostic value of long noncoding RNA SNHG11 in patients with prostate cancer[J]. Horm Metab Res, 2022,54(3):187-193. DOI: 10.1055/a-1745- 8952.
[15] Soerohardjo I, Zulfiqqar A, Widodo I,et al. The combined effect of downregulated RB1 and overexpressed lncRNA SSTRS-AS1 on prediction time to castration-resistant prostate cancer: indonesian cohort studies[J]. Turk J Urol, 2022 ,48(2):112-117. DOI: 10.5152/tud.2022.21282.
[16] 姜秋慧,宋晓霞. lncRNA CCAT1在子宫内膜癌组织中的表达及其与病理参数的关系[J]. 国际医药卫生导报,2022,28(24):3423-3425. DOI:10.3760/cma.j.issn.1007-1245. 2022.24.003.
[17] Li Y, Yan B, Wang X,et al. ALKBH5-mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9[J]. J Cell Mol Med, 2022,26(2):385-398.DOI: 10.1111/jcmm.17091.
[18] Mou J, Wang B, Liu Y,et al. FER1L4: a long non-coding RNA with multiple roles in the occurrence and development of tumors[J]. Curr Pharm Des, 2022,28(16):1334-1341. DOI: 10.2174/1381612828666220324141016.
[19] Wan L, Gu D, Jin X. LncRNA NCK1-AS1 promotes malignant cellular phenotypes of laryngeal squamous cell carcinoma via miR-137/NCK1 axis[J]. Mol Biotechnol, 2022 ,64(8):888-901.DOI: 10.1007/s12033-022-00469-1.
[20] Lu B, Li X, Miao W,et al. LncRNA ZFAS1 promotes laryngeal cancer progression through RBFOX2-mediated MENA alternative splicing[J]. Environ Toxicol, 2023 ,38(3):522-533.DOI: 10.1002/tox.23695.
[21] Wan L, Gu D, Li P. LncRNA SNHG16 promotes proliferation and migration in laryngeal squamous cell carcinoma via the miR-140-5p/NFAT5/Wnt/β-catenin pathway axis[J]. Pathol Res Pract, 2022 ,229:153727. DOI: 10.1016/j.prp.2021.153727.
[22] Shen N, Duan X, Feng Y,et al. Long non-coding RNA HOXA11 antisense RNA upregulates spermatogenesis-associated serine-rich 2-like to enhance cisplatin resistance in laryngeal squamous cell carcinoma by suppressing microRNA-518a[J]. Bioengineered, 2022,13(1):974-984. DOI: 10.1080/21655979.2021.2016038.
[23] Feng T, Song C, Wu Z,et al. Role of lncRNA MIAT/miR-361-3p/CCAR2 in prostate cancer cells[J]. Open Med (Wars), 2022,17(1):1528-1537.DOI: 10.1515/med-2021- 0380.
[24] Hu R, Wu P, Liu J. LncRNA MAGI2-AS3 inhibits prostate cancer progression by targeting the miR-142-3p[J]. Horm Metab Res, 2022,54(11):754-759. DOI: 10.1055/a-1891- 6864.
[25] Zhu W, Sheng D, Shao Y,et al. STAT3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression[J]. Mol Cell Biochem,2022,477(3):865-875.DOI: 10.1007/s11010-021-04284-1.
[26] Zhao D, Hou Y. Long non-coding RNA nuclear-enriched abundant transcript 1 (LncRNA NEAT1) upregulates Cyclin T2 (CCNT2) in laryngeal papilloma through sponging miR-577/miR-1224-5p and blocking cell apoptosis[J]. Bioengineered, 2022,13(1):1828-1837. DOI: 10.1080/21655979.2021.2017653.
[27] Guo F, Gao Y, Sui G,et al. miR-375-3p/YWHAZ/β-catenin axis regulates migration, invasion, EMT in gastric cancer cells[J]. Clin Exp Pharmacol Physiol,2019,46(2):144-152.DOI: 10.1111/1440-1681.13047.
[28] Li Q, Huyan T, Cai S,et al. The role of exosomal miR-375-3p: a potential suppressor in bladder cancer via the Wnt/β-catenin pathway[J]. FASEB J, 2020,34(9):12177-12196. DOI: 10.1096/fj.202000347R.
[29] Wang S, Xu L, Zhang Z,et al. Overexpressed miR-375-loaded restrains development of cervical cancer through down-regulation of frizzled class receptor 4 (FZD4) with liposome nanoparticle as a carrier[J]. J Biomed Nanotechnol, 2021,17(9):1882-1889. DOI: 10.1166/jbn.2021.3145.
[30] Dai F, Xie Z, Yang Q,et al. MicroRNA-375 inhibits laryngeal squamous cell carcinoma progression via targeting CST1[J]. Braz J Otorhinolaryngol,2022,88 Suppl 4:S108-S116. DOI: 10.1016/j.bjorl.2022.06.005.